SG11201407387UA - Use of ghrelin receptor inverse agonists or antagonists for treating sleep disorders - Google Patents

Use of ghrelin receptor inverse agonists or antagonists for treating sleep disorders

Info

Publication number
SG11201407387UA
SG11201407387UA SG11201407387UA SG11201407387UA SG11201407387UA SG 11201407387U A SG11201407387U A SG 11201407387UA SG 11201407387U A SG11201407387U A SG 11201407387UA SG 11201407387U A SG11201407387U A SG 11201407387UA SG 11201407387U A SG11201407387U A SG 11201407387UA
Authority
SG
Singapore
Prior art keywords
rule
international
lllll
iii
treating sleep
Prior art date
Application number
SG11201407387UA
Other languages
English (en)
Inventor
William S Denney
Margaret Jackson
Gabriele Sonnenberg
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of SG11201407387UA publication Critical patent/SG11201407387UA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SG11201407387UA 2012-06-04 2013-05-21 Use of ghrelin receptor inverse agonists or antagonists for treating sleep disorders SG11201407387UA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261655177P 2012-06-04 2012-06-04
US201361812416P 2013-04-16 2013-04-16
PCT/IB2013/054177 WO2013182933A1 (en) 2012-06-04 2013-05-21 Use of ghrelin receptor inverse agonists or antagonists for treating sleep disorders

Publications (1)

Publication Number Publication Date
SG11201407387UA true SG11201407387UA (en) 2014-12-30

Family

ID=48700662

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201407387UA SG11201407387UA (en) 2012-06-04 2013-05-21 Use of ghrelin receptor inverse agonists or antagonists for treating sleep disorders

Country Status (16)

Country Link
US (1) US9370516B2 (cg-RX-API-DMAC7.html)
EP (1) EP2854856B1 (cg-RX-API-DMAC7.html)
JP (1) JP6165852B2 (cg-RX-API-DMAC7.html)
KR (1) KR101708989B1 (cg-RX-API-DMAC7.html)
CN (1) CN104334193A (cg-RX-API-DMAC7.html)
AU (1) AU2013273263B2 (cg-RX-API-DMAC7.html)
BR (1) BR112014029577A2 (cg-RX-API-DMAC7.html)
CA (1) CA2874196C (cg-RX-API-DMAC7.html)
ES (1) ES2716303T3 (cg-RX-API-DMAC7.html)
HK (1) HK1202459A1 (cg-RX-API-DMAC7.html)
IL (1) IL235883A0 (cg-RX-API-DMAC7.html)
MX (1) MX2014014813A (cg-RX-API-DMAC7.html)
RU (1) RU2600895C2 (cg-RX-API-DMAC7.html)
SG (1) SG11201407387UA (cg-RX-API-DMAC7.html)
WO (1) WO2013182933A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201408672B (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105175272A (zh) * 2015-08-31 2015-12-23 吴玲 制备r-5-溴-1-氨基茚满的方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9606805D0 (en) 1996-03-30 1996-06-05 Glaxo Wellcome Inc Medicaments
US6414002B1 (en) 1999-09-22 2002-07-02 Bristol-Myers Squibb Company Substituted acid derivatives useful as antidiabetic and antiobesity agents and method
WO2004058160A2 (en) * 2002-12-20 2004-07-15 The Mclean Hospital Corporation Compounds for the normalization of the sleep/wake cycle
US20050171132A1 (en) * 2003-09-26 2005-08-04 Zhili Xin Diaminopyrimidine derivatives as selective growth hormone secrectgogue receptor (GHS-R) antagonists
JP2007537207A (ja) * 2004-05-14 2007-12-20 ノボ ノルディスク アクティーゼルスカブ 一定の中枢神経疾患の治療のためのグレリンアンタゴニストの使用
US20090253673A1 (en) * 2006-07-12 2009-10-08 Min Ge Substituted Pyrazoles as Ghrelin Receptor Antagonists
US8309530B2 (en) * 2009-02-04 2012-11-13 Washington State University Compositions and methods for modulating ghrelin-mediated conditions
ES2557895T3 (es) * 2010-03-19 2016-01-29 Pfizer Inc Derivados de 2,3-dihidro-1H-inden-1-il-2,7-diazaespiro[3.6]nonano y su uso como antagonistas o agonistas inversos del receptor de grelina

Also Published As

Publication number Publication date
KR20150013236A (ko) 2015-02-04
US9370516B2 (en) 2016-06-21
MX2014014813A (es) 2015-02-12
AU2013273263A1 (en) 2014-11-27
EP2854856B1 (en) 2019-01-23
JP2015518876A (ja) 2015-07-06
US20150119381A1 (en) 2015-04-30
HK1202459A1 (en) 2015-10-02
CA2874196A1 (en) 2013-12-12
WO2013182933A1 (en) 2013-12-12
AU2013273263B2 (en) 2017-08-24
RU2600895C2 (ru) 2016-10-27
CN104334193A (zh) 2015-02-04
ZA201408672B (en) 2016-09-28
CA2874196C (en) 2016-12-06
KR101708989B1 (ko) 2017-02-21
JP6165852B2 (ja) 2017-07-19
ES2716303T3 (es) 2019-06-11
IL235883A0 (en) 2015-01-29
EP2854856A1 (en) 2015-04-08
RU2014146109A (ru) 2016-07-27
BR112014029577A2 (pt) 2017-06-27

Similar Documents

Publication Publication Date Title
SG11201808990QA (en) Compositions for topical application of compounds
SG11201408318RA (en) Compositions and methods for transmucosal absorption
SG11201908330PA (en) Farnesoid x receptor agonists and uses thereof
SG11201909955XA (en) Formulations of anti-lag3 antibodies and co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies
SG11201407548UA (en) Treatment of amd using aav sflt-1
SG11201903882VA (en) Il-2 variants for the treatment of autoimmune diseases
SG11201909949XA (en) Targeted immunotolerance
SG11201408140QA (en) Crystalline forms of an androgen receptor modulator
SG11201810628XA (en) Nasal pharmaceutical compositions with a porous excipient
SG11201811491YA (en) Quinazoline and indole compounds to treat medical disorders
SG11201408095XA (en) Fibroblast growth factor 21 proteins
SG11201407228PA (en) N-aryltriazole compounds as lpar antagonists
SG11201408044QA (en) NOVEL 4-(SUBSTITUTED-AMINO)-7H-PYRROLO[2,3-d]PYRIMIDINES AS LRRK2 INHIBITORS
SG11201811230RA (en) Compositions and methods for reducing ocular neovascularization
SG11201407397WA (en) Formulations and methods for vaginal delivery of antiprogestins
SG11201407220YA (en) N-alkyltriazole compounds as lpar antagonists
SG11201804758QA (en) Aqueous pharmaceutical formulation comprising anti-pd-1 antibody avelumab
SG11201805320XA (en) Materials and methods for treatment of amyotrophic lateral sclerosis and/or frontal temporal lobular degeneration
SG11201407580YA (en) Composition comprising two antibodies engineered to have reduced and increased effector function
SG11201805709RA (en) Anti-pro/latent myostatin antibodies and methods of use thereof
SG11201907804QA (en) Pharmaceutical composition comprising selexipag
SG11201809499UA (en) Processes for preparing phosphorodiamidate morpholino oligomers
SG11201406973PA (en) Complement pathway modulators and uses thereof
SG11201807784SA (en) 3-desoxy derivative and pharmaceutical compositions thereof
SG11201908517XA (en) Pyrimidinyl-pyridyloxy-naphthyl compounds and methods of treating ire1-related diseases and disorders